Petros Christopoulos
Overview
Explore the profile of Petros Christopoulos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
1868
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Janke F, Gasser M, Angeles A, Riediger A, Gortz M, Appenheimer L, et al.
J Exp Clin Cancer Res
. 2025 Mar;
44(1):87.
PMID: 40055810
Background: Outcomes under anti-PD-(L)1 therapy have been variable in advanced non-small cell lung cancer (NSCLC) without reliable predictive biomarkers so far. Targeted next-generation sequencing (NGS) of circulating tumor DNA (ctDNA)...
3.
Abooali M, Schlichtner S, Lei X, Aliu N, Ruggiero S, Loges S, et al.
Cancer Lett
. 2025 Feb;
616:217581.
PMID: 39983894
V-domain Ig-containing suppressor of T cell activation (VISTA) is a unique immune checkpoint protein, which was reported to display both receptor and ligand activities. However, the mechanisms of regulation of...
4.
Hofman P, Christopoulos P, DHaene N, Gosney J, Normanno N, Schuuring E, et al.
Lung Cancer
. 2025 Feb;
201:108107.
PMID: 39904223
The implementation of biomarker testing for targeted therapies and immune checkpoint inhibitors is a cornerstone in the management of metastatic and locally advanced non-small cell lung cancer (NSCLC), playing a...
5.
Thomas M, Christopoulos P, Iams W, Mazieres J, Cortot A, Peled N, et al.
J Comp Eff Res
. 2025 Jan;
14(2):e240127.
PMID: 39836056
exon 14 ex14) skipping occurs in 3-4% of non-small-cell lung cancer (NSCLC) cases. Low frequency of this alteration necessitated open-label, single-arm trials to investigate MET inhibitors. Since broad MET biomarker...
6.
Zerdes I, Kamali C, Johannsdottir B, Blasi M, Assmann C, Kazdal D, et al.
Lung Cancer
. 2024 Dec;
199:108065.
PMID: 39705826
Introduction: Several prognostic scores were developed for non-small-cell lung cancer (NSCLC) patients with brain metastases (BM), though limited data reported for the KRAS-mutated subgroup. KRAS-targeted therapies have improved extracranial and...
7.
Kramer A, Hahnemann L, Schunn F, Grott C, Thomas M, Christopoulos P, et al.
Clin Transl Radiat Oncol
. 2024 Dec;
50:100893.
PMID: 39651456
Introduction: Brain metastases (BM) are the most common malignancy in the central nervous system (CNS) and observed in approximately 30% of cancer patients. Brainstem metastases (BSM) are challenging because of...
8.
Saalfeld F, Moller J, Christopoulos P, Wenzel C, Rasokat A, Wang X, et al.
Eur J Cancer
. 2024 Oct;
213:115065.
PMID: 39423775
Introduction: Small cell transformation (SCT) is a typical mechanism of adaptive resistance to third generation epidermal growth factor receptor inhibitors (EGFRi) which have become the standard of care for EGFR-driven...
9.
Wiesweg M, Kuter C, Schnorbach J, Keyl J, Metzenmacher M, Cvetkovic J, et al.
Int J Cancer
. 2024 Sep;
156(4):776-787.
PMID: 39319506
Oligometastatic (OMD) non-small cell lung cancer (NSCLC) is a distinct but heterogeneous entity. Current guidelines recommend systemic therapy and consolidation with local ablative therapy (LAT). However, evidence regarding the optimal...
10.
Dernbach G, Kazdal D, Ruff L, Alber M, Romanovsky E, Schallenberg S, et al.
Eur J Cancer
. 2024 Sep;
211:114292.
PMID: 39276594
Introduction: Molecular profiling of lung cancer is essential to identify genetic alterations that predict response to targeted therapy. While deep learning shows promise for predicting oncogenic mutations from whole tissue...